Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Common Equity (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Common Equity for 6 consecutive years, with $4.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 22.88% year-over-year to $4.3 billion, compared with a TTM value of $4.3 billion through Dec 2025, down 22.88%, and an annual FY2025 reading of $5.2 billion, down 19.56% over the prior year.
  • Common Equity was $4.3 billion for Q4 2025 at Roivant Sciences, down from $4.8 billion in the prior quarter.
  • Across five years, Common Equity topped out at $6.6 billion in Q4 2023 and bottomed at $1.3 billion in Q3 2023.
  • Average Common Equity over 5 years is $3.4 billion, with a median of $2.3 billion recorded in 2021.
  • The sharpest move saw Common Equity tumbled 37.65% in 2022, then surged 361.38% in 2023.
  • Year by year, Common Equity stood at $2.2 billion in 2021, then tumbled by 36.49% to $1.4 billion in 2022, then skyrocketed by 361.38% to $6.6 billion in 2023, then dropped by 15.93% to $5.5 billion in 2024, then fell by 22.88% to $4.3 billion in 2025.
  • Business Quant data shows Common Equity for ROIV at $4.3 billion in Q4 2025, $4.8 billion in Q3 2025, and $4.8 billion in Q2 2025.